Inclusion Criteria:

          -  Age ≥ 18 years

          -  Participants must have pathologically confirmed, newly diagnosed acute myeloid
             leukemia (AML). The AML may be either:

               -  De Novo: AML in patients with no clinical history of prior myelodysplastic
                  syndrome (MDS), myeloproliferative disorder, or exposure to potentially
                  leukemogenic therapies or agents

               -  Secondary AML (sAML): refers to an acute leukemic process (1) evolving from known
                  prior myelodysplasia, myeloproliferative disorder, or aplastic anemia with or
                  without treatment or; (2) as a product of previous exposure to a proven
                  leukemogenic chemotherapeutic agent

          -  Eligible for intensive induction chemotherapy, according to their treating physician

          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

          -  Left ventricular ejection fraction > 50% as measured by echocardiogram or MUGA scan

          -  Must not have received systemic prior antineoplastic therapy for treatment for the
             newly diagnosed AML, including radiation therapy, except hydroxyurea for the purposes
             of cytoreduction. Patients may also have received all-trans retinoic acid (ATRA) if
             there is an early suspicion of acute promyelocytic leukemia (APL, M3-AML), although if
             confirmed to have APL these patients will be excluded from the study.

          -  Adequate hepatic function per local laboratory reference ranges as follows:

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0X ULN

               -  Total bilirubin ≤ 2.0 x ULN (unless bilirubin rise is known to be due to
                  Gilbert's syndrome or of non-hepatic origin)

          -  The effects of venetoclax on the developing human fetus are unknown. For this reason
             and because other chemotherapeutic agents are known to be teratogenic, women of
             child-bearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation. Should a woman become pregnant or suspect she is pregnant
             while she or her partner is participating in this study, she should inform her
             treating physician immediately. Women should use contraceptives for at least 30 days
             following the last dose of venetoclax. Men treated or enrolled on this protocol must
             also agree to use adequate contraception prior to the study, for the duration of study
             participation, and 4 months after completion of therapy.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Diagnosis of Acute promyelocytic leukemia (APL) or AML with favorable cytogenetics
             [t(8;21), inv(16), t(16;16)]

          -  Patients < 60 years old with NPM1-mutated AML:

          -  Patients with FLT3-mutated AML (TKD or ITD).

          -  Patients with acute leukemia with ambiguous lineage or mixed phenotype

          -  Patients that have received strong and/or moderate CYP3A inducers within 7 days prior
             to the initiation of study treatment.

          -  Subject has consumed grapefruit, grapefruit products, Seville oranges (including
             marmalade containing Seville oranges) or Starfruit within 3 days prior to the
             initiation of study treatment.

          -  Patients who have had prior systemic cytotoxic chemotherapy or radiotherapy for AML
             (excluding patients with therapy-related AML), except for hydroxyurea or 6-MP as
             noted. Empiric intrathecal chemotherapy during a diagnostic lumbar puncture is
             allowed, as long as CNS disease is not suspected.

          -  Patients treated with prior hypomethylating therapy (such as azacitidine or
             decitabine).

          -  Patients who will exceed a lifetime anthracycline exposure of >550 mg/m2 daunorubicin
             or equivalent (or >400 mg/m2 daunorubicin or equivalent in the event of prior
             mediastinal radiation) if they receive the maximum potential exposure to
             anthracyclines per protocol (including both induction and consolidation cycles.

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances. Individuals with a history of other malignancies are eligible
             if they have been disease-free for at least 3 years and are deemed by the investigator
             to be at low risk for recurrence of that malignancy. Individuals with the following
             cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer
             in situ, breast DCIS, and basal cell or squamous cell carcinoma of the skin.

          -  Current clinical central nervous system (CNS) symptoms deemed by the investigator to
             be related to leukemic CNS involvement (no lumbar puncture required, clinical
             assessment per investigator's judgment is sufficient).

          -  Prior bone marrow transplantation for a myeloid malignancy

          -  Participants who are receiving any other investigational agents within the prior 14
             days.

          -  Currently clinically active hepatitis C or hepatitis B infection, as suggested by
             serology or viral load.

          -  Human immunodeficiency virus (HIV)-infected participants. Patients with no detectable
             viral load on a stable anti-viral regimen may be eligible, after discussion with the
             study overall PI.

          -  Current or history of congestive heart failure New York Heart Association (NYHA) class
             3 or 4, or any history of documented diastolic or systolic dysfunction (LVEF <50%, as
             measured by MUGA scan or echocardiogram). Prior to study entry, any ECG abnormality at
             screening has to be documented by the investigator as not medically relevant.

          -  Known hypersensitivity to the trial drugs or other contraindication to standard "7+3"
             induction chemotherapy.

          -  WBC > 25 x 109/L. Note: hydroxyurea is permitted to meet this criterion

          -  Patients who might refuse to receive blood products and/or have a hypersensitivity to
             blood products

          -  Patients with clinically significant persistent electrolyte abnormalities such as
             hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and
             hypermagnesemia of Grade > 1 per NCI CTCAE, v5.0. Treatment for correction of above
             electrolyte imbalances is permitted during screening to meet eligibility.

          -  Uncontrolled intercurrent illness including, but not limited to, clinically ongoing or
             active infection requiring intravenous antibiotics (IV antibiotics are allowed if
             infection is deemed to be controlled), symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Known GI disease or GI procedures that could interfere with the oral absorption or
             tolerance of the study drugs. Examples include, but are not limited to partial
             gastrectomy, history of small intestine surgery, and celiac disease.

          -  Pregnant women are excluded from this study because venetoclax and azacitidine, along
             with standard induction chemotherapy, carries the potential for teratogenic or
             abortifacient effects. Because there is potential risk for adverse events in nursing
             infants secondary to treatment of the mother with venetoclax as well as azacitidine,
             cytarabine, daunorubicin and idarubicin, breastfeeding should be avoided. Confirmation
             that the subject is not pregnant must be established by a negative serum ß-human
             chorionic gonadotropin (ß-hCG) pregnancy test result obtained during screening.
             Pregnancy testing is not required for post-menopausal or surgically sterilized women.

          -  Patients with psychological, familial, social, or geographic factors that otherwise
             preclude them from giving informed consent, following the protocol, or potentially
             hamper compliance with study treatment and follow-up.

          -  Patients who are otherwise felt unable to comply with the protocol, in the opinion of
             the investigator.